Relmada Therapeutics, Inc. Files a Litigation Against Laidlaw & Company (UK) Ltd.

Laidlaw & Company (UK) Ltd. provides wealth management and investment banking services to individuals and institutions in the United Kingdom and the United States. Its investment services include mezzanine and placement of debt capital with institutional investors. Equity with high-net-worth and institutional and retail investor placement, and acquisition and financing. The company also offers initial public offerings, AIM-listed transactions in the United Kingdom market, the United States trading markets, and arrangement of public exchange listings. The company’s investment banking system also include advisory services on acquisition and finance, fairness options, financial restructure, and divestitures.

Relmada Therapeutics, Inc. is a clinical company that develops novel therapies for chronic pain treatments. The company announces that it filed an amendment motion to amend its litigation against Laidlaw & Company (UK) Ltd. in the federal District Court of Nevada. The motion to file the amendment complaint was part of the litigation that it has tabled in U.S. District Court of Nevada. This amendment claim includes a legal complaint based on Laidlaw’s fiduciary duty breach that it owed to Relmada when it disclosed information it had as an investment banker concerning Relmada. Relmada also seeks monetary compensation that arises from costs and fees it incurred responding to Laidlaw’s misleading and false proxy material in December 2015.

Relmada Therapeutics, Inc. also notes that the court had previously issued an associated injunction and restraining order against Laidlaw and its core principals James Ahern and Mather Eitner. This occurred as a result of their dissemination of misleading material. Relmada’s board of directors believe that Laidlaw has to compensate it for the accrued damages it suffered from its actions. It also believes that Laidlaw should be prevented from harming the company in any way in the future.

Laidlaw has served as a first investment banker for Relmada and made it a placement agent in December 2011.